Our Vision

Velanidi is pioneering nanometer-scale, computer-based pharmaceuticals (“microelectronic medicines”) as an entirely novel class of cancer, autoimmune and infectious disease treatment.

For the first time in history, humankind now can fabricate microelectronic transistors at a nanometer scale small enough to enable medical devices that are at the size scale of cancer and tumor cells, viruses and bacteria. Leveraging this recent and remarkable technological breakthrough, Velanidi is designing and developing its pathogen-destroying, microelectronic medicine devices to be “smart,” capable of computerized (logic-based) decisions. The incorporation of logic into its design means that Velanidi’s microelectronic medicines can discriminate between pathogenic cells and healthy (normal) cells.

Velanidi’s microelectronic medicine technology also is designed to solve a notorious challenge in disease eradication, in which pathogens continuously develop resistance mechanisms to biochemically-based treatments. Velanidi’s underlying hypothesis is that a pathogen cannot develop a corresponding resistance to our proprietary microelectronic medicine design. This is because Velanidi’s microelectronic medicine technology employs a non-biomimetic technique to eradicate pathogenic cells, leaving normal, healthy cells unharmed. That is, each individual microelectronic medicine “device” electro-ablatively destroys (“zaps”) a cell, if (and only if) the logic-based integrated circuitry of the microelectronic medicine device has identified the cell as pathogenic. For example, a microelectronic medicine device can distinguish a pathogenic tumor cell from a healthy human cell through circuitry that only activates the microelectronic medicine device when a tumor antigen is bound, while not activating the microelectronic medicine device if a human (safety) antigen is bound. Thus, our microelectronic medicine design offers unprecedented programmable selectivity, while electro-ablation bypasses nearly all contemporary disease treatment modalities that attempt to exploit some biochemical process, processes against which pathogens have developed counteracting and resistant mechanisms.

Velanidi currently is researching, testing and refining the microelectronic medicine device subsystems that allow it to sense and eradicate pathogenic cells. Development for clinical application through in-vivo models and regulatory-level trials will follow, once the microelectronic medicine device has been demonstrated to be effective in-vitro.